X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47) 47
male (32) 32
female (30) 30
aged (26) 26
middle aged (24) 24
hematology (22) 22
index medicus (19) 19
adult (18) 18
oncology (18) 18
treatment outcome (13) 13
aged, 80 and over (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
japan (9) 9
medicine & public health (9) 9
prognosis (9) 9
transplantation (9) 9
leukemia-lymphoma, adult t-cell - drug therapy (8) 8
chemotherapy (7) 7
disease-free survival (7) 7
leukemia (7) 7
leukemia/lymphoma (6) 6
lymphoma (6) 6
medicine, general & internal (6) 6
retrospective studies (6) 6
antineoplastic agents - therapeutic use (5) 5
cancer (5) 5
disease progression (5) 5
drug therapy, combination (5) 5
lymphomas (5) 5
recurrence (5) 5
animals (4) 4
antineoplastic agents - administration & dosage (4) 4
cell line (4) 4
chemiluminescence (4) 4
combined modality therapy (4) 4
expression (4) 4
hematopoietic stem cell transplantation (4) 4
imatinib (4) 4
infection (4) 4
kaplan-meier estimate (4) 4
leukemia-lymphoma (4) 4
leukemia-lymphoma, adult t-cell - mortality (4) 4
martensitic transformation (4) 4
neutrophils - drug effects (4) 4
polymerase chain reaction (4) 4
proportional hazards models (4) 4
reactive oxygen species (4) 4
stem cell transplantation (4) 4
stem cells (4) 4
t cells (4) 4
abridged index medicus (3) 3
adolescent (3) 3
amorphous (3) 3
analysis (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
atl (3) 3
benzamides (3) 3
biochemistry & molecular biology (3) 3
bone-marrow-transplantation (3) 3
cisplatin - pharmacology (3) 3
combination chemotherapy (3) 3
cytotoxicity (3) 3
dasatinib (3) 3
dexamethasone - administration & dosage (3) 3
diagnosis, differential (3) 3
dna probes (3) 3
doxorubicin - administration & dosage (3) 3
drug resistance (3) 3
drug resistance - genetics (3) 3
follow-up studies (3) 3
hematopoietic stem cells (3) 3
imatinib mesylate (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
leukemia-lymphoma, adult t-cell - therapy (3) 3
leukemia-lymphoma, adult t-cell - virology (3) 3
luminescent measurements (3) 3
materials science, multidisciplinary (3) 3
non-hodgkins-lymphoma (3) 3
prednisolone - administration & dosage (3) 3
reactive oxygen species - metabolism (3) 3
remission induction (3) 3
sputtering (3) 3
survival (3) 3
thin film (3) 3
time factors (3) 3
titanium-nickel (3) 3
transplantation, autologous (3) 3
vincristine - administration & dosage (3) 3
young adult (3) 3
acute promyelocytic leukemia (2) 2
adult t-cell leukaemia-lymphoma (2) 2
adult t‐cell leukaemia‐lymphoma (2) 2
all-trans retinoic acid (2) 2
allografts (2) 2
altern (2) 2
aluminum (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antibodies, monoclonal, murine-derived (2) 2
antiprotozoal agents - therapeutic use (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Hematology, ISSN 0925-5710, 12/2016, Volume 104, Issue 6, pp. 639 - 640
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s12185-016-2107-y 
Medicine & Public Health | Hematology | Oncology | HEMATOLOGY | Cell Proliferation | Cytoplasmic Granules - pathology | Lymph Nodes - pathology | Lymphoma, Follicular - pathology | Bone Marrow - pathology | Humans | Male | Aged | Plasma Cells - pathology | Lymphomas
Journal Article
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2015, Volume 169, Issue 5, pp. 672 - 682
Summary This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐CC chemokine receptor 4... 
mogamulizumab | randomized phase II study | CCR4 | adult T‐cell leukaemia‐lymphoma | antibody therapy | Adult T-cell leukaemia-lymphoma | Mogamulizumab | Antibody therapy | Randomized phase II study | adult T-cell leukaemia-lymphoma | MONOCLONAL-ANTIBODY KW-0761 | RECEPTOR | LEUKEMIA/LYMPHOMA | HEMATOLOGY | EXPRESSION | ASSOCIATION | TRANSPLANTATION | Doxorubicin - therapeutic use | Nitrosourea Compounds - adverse effects | Prednisolone - adverse effects | Nitrosourea Compounds - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Carboplatin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Aged, 80 and over | Adult | Female | Prednisolone - therapeutic use | Etoposide - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Etoposide - therapeutic use | Treatment Outcome | Leukemia-Lymphoma, Adult T-Cell - pathology | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Chemotherapy | Lymphomas | T cells | Leukemia | Cancer | Haematological Malignancy | Research Paper
Journal Article
Blood, ISSN 0006-4971, 08/2010, Volume 116, Issue 8, pp. 1211 - 1219
Journal Article
International Journal of Hematology, ISSN 0925-5710, 2/2018, Volume 107, Issue 2, pp. 185 - 193
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 24, pp. 2570 - 2577
Journal Article
Cancer Science, ISSN 1347-9032, 06/2010, Volume 101, Issue 6, pp. 1480 - 1486
Journal Article
Internal Medicine, ISSN 0918-2918, 2016, Volume 55, Issue 21, pp. 3175 - 3180
Journal Article